Inflammation may play a role in ovarian cancer carcinogenesis through the production of toxic oxidants and bioactive substances, increasing the chances of DNA damage and mutagenesis ([@bib16]). Analgesic drugs, such as aspirin and other nonsteroidal anti-inflammatory drugs (NSAIDs), have anti-inflammatory properties and have been associated with reduced risks of several malignancies ([@bib24]; [@bib7]; [@bib3]; [@bib21]; [@bib15]). Another commonly used type of analgesic medication, acetaminophen, has weak anti-inflammatory activity, but may reduce cancer risk through antigonadotropic effects ([@bib4]) that may be particularly relevant to ovarian cancer.

The existing literature examining analgesic drug use and ovarian cancer risk is inconsistent, with the majority of studies reporting mild protective associations ([@bib20]; [@bib23]; [@bib27]; [@bib19]) or no association ([@bib13]; [@bib11]; [@bib14]), with few suggesting weak positive relationships ([@bib9]; [@bib28]). A meta-analysis of 17 studies concluded that the existing body of evidence does not clearly support the presence of an association between analgesic use and ovarian cancer risk ([@bib17]). However, a recent, well-powered pooled analysis using data from 12 case--control studies participating in the Ovarian Cancer Association Consortium observed a statistically significant decrease in epithelial ovarian cancer (EOC) risk for aspirin use, a decrease in risk for high-dose non-aspirin NSAID use, and no association for acetaminophen use ([@bib26]).

The majority of published literature examining the relationship between analgesic use and ovarian cancer was conducted in study populations composed predominately of white women, with little representation of African American (AA) women. There are several indications that a differing risk profile may be evident by race; published studies have suggested that AA women have higher inflammatory marker levels (e.g., interleukin-6, C-reactive protein) than white women ([@bib2]; [@bib10]; [@bib18]) and that there are differences in patterns of analgesic use by race ([@bib29]). To our knowledge, only one study ([@bib25]) has evaluated race-specific associations for analgesic use and risk of EOC. Using the Multiethnic Cohort Study, [@bib25] reported a weak inverse association, although not significant, between analgesic drug use and EOC risk for AA women. Although this is a large prospective study of ∼60 000 women, the inferences were limited by the small number of AA ovarian cancer cases (*n*=41). Other studies including AA women had relatively small samples of AA women with inadequate power to assess race-specific associations ([@bib23]; [@bib28]). To overcome these challenges, the present analysis utilised the largest study of EOC in AA women, to date, to examine EOC risk associated with analgesic medication use exclusively among AA women.

Materials and methods
=====================

Study population
----------------

The African American Cancer Epidemiology Study (AACES) is a population-based case--control study examining risk factors for EOC exclusively among AA women. The AACES is a collaborative effort between 11 sites, including Alabama, Georgia, Illinois, Louisiana, Michigan, New Jersey, North Carolina, Ohio, South Carolina, Tennessee, and Texas. A detailed description of methods for AACES has been published elsewhere ([@bib22]). Briefly, cases were identified through rapid case ascertainment at SEER and state cancer registries, gynaecologic oncology departments, or hospitals. Eligibility criteria for the cases included: self-identification of AA race, aged 20--79 years, and newly diagnosed with invasive EOC after December 2010. The AA controls were identified through random digit dialing, and were frequency matched to cases by 5-year age category and state of residence. Women were excluded if previously diagnosed with EOC or if they had a bilateral oophorectomy. The AACES participants completed a telephone interview, including questions on demographic characteristics, reproductive history, oral contraceptive use, hormone therapy, family history of cancers, medication use, and a variety of lifestyle characteristics (e.g., smoking, physical activity). A short form of the questionnaire could also be completed in an effort to increase participation for women who would have otherwise refused. The study protocol was approved by the Institutional Review Board at each site, and informed consent was obtained for all participants.

As of August 2015, AACES has enrolled a total of 593 cases and 750 controls (*N*=1343). Of these, 71 women completed the short questionnaire, 52 cases and 19 controls. As the short form of the questionnaire did not inquire about analgesic medication use, the data set was restricted to include only those women completing the long form of the questionnaire (*N*=1272; 541 cases and 731 controls).

Analgesic drug use
------------------

In the questionnaire, participants were asked to recall any medications for pain or inflammation that were taken regularly, defined as at least once a week or at least 5 days out of the month, at any point in their lifetime. Examples of analgesic drugs and indications of use were provided to aid in recollection. Women who responded affirmatively to ever using pain or inflammation medications were then asked the name of the drug (including dosing information, if available), the reason for using the drug, how many days per month taken, age of first and last use, and the duration of use in months or years. This series of questions was repeated if the participant reported using more than one drug in her lifetime, with no participant reporting use of more than 10 analgesic drugs. The names of each drug were reviewed and categorised into the following groups: aspirin, non-aspirin NSAIDs, and acetaminophen. Some medications contained a combination of these analgesic types (e.g., aspirin and acetaminophen) and women who reported taking them were categorised as having used both types of analgesics. Any reported medication that did not fit into one of these categories (e.g., muscle relaxants, opioids, anti-epileptics) was considered as nonuse. To successfully model a time period of analgesic use that was not influenced by potential symptoms of an undiagnosed EOC, women who reported initiation of analgesic drug use within the year before the reference date (cases: diagnosis of EOC; controls: time of interview) were categorised as nonusers. In addition, a women who reported a duration of use of \<6 months or any case who reported initiation of analgesic drug use after her EOC diagnosis was categorised as a nonuser.

Statistical analyses
--------------------

Multivariate unconditional logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (95% CIs) for the relationship between use of analgesic medications and risk of EOC. Each medication type was examined in a separate model with women who never used any analgesic medication serving as the referent group. In addition, the association of any type of NSAID (aspirin and non-aspirin NSAIDs, but not acetaminophen) with EOC risk was also examined. Use of aspirin, non-aspirin NSAIDs, and acetaminophen was further examined by frequency of use (\<30 times per month, daily), duration of use (\<5 years, ⩾5 years), combined frequency and duration of use (\<30 times per month for \<5 years, daily for \<5 years, \<30 times per month for ⩾5 years, daily for ⩾5 years), and indication of use (arthritis, menstrual cramps, injury/pain, headache, and heart disease). Because of insufficient data on dose for non-aspirin NSAIDs and acetaminophen, the effect of dose on EOC risk was assessed for aspirin only (low dose: \<100 mg; high dose: ⩾100 mg).

The following *a priori* confounders were adjusted for in all models: age (age at diagnosis for cases and age at the time of interview for controls); study site (Alabama, Georgia and Tennessee combined (because of small sample sizes and geographic similarities), Illinois and Michigan combined (because of small sample sizes and geographic similarities), Louisiana, New Jersey, North Carolina, Ohio, South Carolina, and Texas); education (high school graduate or less, some post-high school training, and college or graduate degree); income (\<\$25 000, \$25 000--\$49 999, \$50 000--\$74 999, and ⩾\$75 000); parity (nulliparous, 1, 2, 3, or more live births); family history of a first-degree relative with breast or ovarian cancer (yes, no); tubal ligation (yes, no); body mass index (\<25 kg m^−2^: underweight and normal weight; 25--29.9 kg m^−2^: overweight; ⩾30 kg m^−2^: obese); oral contraceptive use (ever, never); menopausal status (pre-, peri-, and post-menopause); endometriosis (yes, no); pelvic inflammatory disease (yes, no); mild physical activity (yes, no); and moderate or strenuous physical activity (yes, no). Several comorbid conditions (e.g., heart disease, osteoporosis, and arthritis) were also evaluated as potential confounders, but no appreciable change in the effect estimates was observed and these conditions were not included in the final models. As women commonly reported use of more than one type of analgesic (e.g., of the women reporting acetaminophen use, 40% also reported using non-aspirin NSAIDs), use of (frequency of, duration of, indication of) the other analgesic types were simultaneously adjusted for in regression models. Therefore, the estimated associations in the present study reflect the independent effect of that type of analgesic without confounding by use of other analgesic types.

Finally, potential effect modification by two pro-inflammatory factors, BMI and smoking, was evaluated to determine whether analgesic medication use may be particularly beneficial for specific subgroups with higher inflammation. All analyses were conducted using SAS, Version 9.3 (SAS, Cary, NC, USA).

Results
=======

A total of 1272 subjects, 541 cases and 731 controls, were included in the analysis. [Table 1](#tbl1){ref-type="table"} describes demographic, reproductive, and lifestyle characteristics of cases and controls. Compared with controls, cases were more likely to be older (because of collapsing of 5-year age categories that were used for frequency matching), to have a high school education or less, to be nulliparous, to have a family history of a first-degree relative with breast or ovarian cancer, to have had endometriosis, and to have had pelvic inflammatory disease, and cases were less likely to have had tubal ligation, to use oral contraceptives, and to engage in mild intensity physical activity. The majority of cases were diagnosed with serous EOC (72.8%). Overall, 467 women reported use of any analgesic medication (36.7%). Of those, non-aspirin NSAIDs were the most commonly reported analgesic medication (62.7%), followed by aspirin and acetaminophen, 35.1% and 27.4% respectively (percentages do not equal 100% because of women taking more than one type of analgesic drug).

The associations between analgesic medication use and EOC risk are shown in [Table 2](#tbl2){ref-type="table"}. In comparison with never users of any analgesic medications, women who used any type of NSAIDs, including aspirin and non-aspirin NSAIDs but not acetaminophen, had a 27% lower risk of EOC (OR=0.73, 95% CI=0.54--0.98). No association with EOC risk was observed for women who used a combination of all analgesic drug types (OR=1.03, 95% CI=0.58--1.84). When evaluating use of each analgesic medication in separate models, a statistically significant 44% lower EOC risk was observed for women who reported use of aspirin (OR=0.56, 95% CI=0.35--0.92), and a 26% lower EOC risk (OR=0.74, 95% CI= 0.52--1.05) was observed for non-aspirin NSAID use. Acetaminophen was inversely associated with risk of EOC, although not statistically significant (OR=0.89, 95% CI=0.49--1.62).

[Table 3](#tbl3){ref-type="table"} shows the associations for frequency and duration of use for each analgesic drug and risk of EOC. Irrespective of frequency and duration of aspirin use, inverse associations with risk of EOC were observed. Statistically significant lower risks of EOC were observed for daily aspirin use (OR=0.56, 95% CI=0.34--0.94) and aspirin use for a duration of \<5 years (OR=0.52, 95% CI=0.28--0.98). A significant inverse association with risk of EOC was observed for AA women who occasionally used non-aspirin NSAIDs (\<30 days per month), OR=0.54 (95% CI=0.35--0.83). An inverse association was observed for women who used non-aspirin NSAIDs for a duration of ⩾5 years, although not statistically significant (OR=0.71, 95% CI=0.47--1.07). In combined analyses of frequency and duration of use, inverse associations with EOC risk, although not statistically significant, were observed for all categories of aspirin use. However, a statistically significant lower risk of EOC was present among women who used non-aspirin NSAIDs for \<30 days per month for a duration of ⩾5 years (OR=0.47, 95% CI=0.28--0.79). Although inversely associated, no statistically significant associations were observed for frequency or duration of acetaminophen use.

The most common indication of aspirin use was heart disease prevention (75.3%), whereas arthritis (45.5%) was the most common reason for non-aspirin NSAID use. Significant inverse associations were observed for the most prevalent indication of use for aspirin and non-aspirin NSAIDs, where a 50% lower EOC risk was observed for women using aspirin to prevent heart disease (OR=0.50, 95% CI=0.29--0.85) and a 48% lower EOC risk for women using non-aspirin NSAIDs for arthritis (OR=0.52, 95% CI=0.31--0.88) (data not shown).

The influence of dose for analgesic medications on EOC risk was also examined; however, sufficient data on dose were only present for aspirin use. Of the aspirin users with dosing information (*n*=127), 77.2% reported low-dose aspirin use. Low-dose aspirin users had a more pronounced, statistically significant inverse association with EOC risk, OR=0.54 (95% CI=0.31--0.97), in comparison with high-dose aspirin users, OR=0.78 (95% CI=0.30--2.06) (data not shown).

Presence of effect modification by BMI and smoking on the relationship between analgesic medications and EOC risk was not observed, *P*\<0.05 (data not shown).

Discussion
==========

This is the first study to examine the association between analgesic drug use and EOC risk in a large population of AA women. A statistically significant 44% lower EOC risk and a borderline significant 26% lower EOC risk was observed among aspirin and non-aspirin NSAID users, respectively. Although inversely related, no significant associations for acetaminophen use and EOC risk were observed in this population. The inverse association between analgesic use and EOC was consistent with previous findings from several studies ([@bib23]; [@bib27]; [@bib19]), and especially parallel the findings in the recent pooled analysis ([@bib26]). As with the pooled analysis, a similar inverse association for aspirin use and EOC risk, overall, was observed and especially for low-dose aspirin use, daily aspirin use, and shorter duration of aspirin use (\<5 years). The present study also observed a decreased EOC risk for non-aspirin NSAID use overall and specifically for occasional monthly use (\<30 days per month) for ⩾5 years. The previously published pooled analysis only observed a significant inverse association for high-dose non-aspirin NSAID use ([@bib26]); however, the non-aspirin NSAID use results of the present study were similar to many published studies ([@bib6]; [@bib23]; [@bib12]; [@bib27]; [@bib19]).

Interestingly, the inverse relationship between analgesic use and EOC risk observed in the present study was more pronounced than those observed in predominately white populations. In the only other study to conduct race-specific analyses for analgesic use and EOC risk, AA women had the strongest inverse association between aspirin and non-aspirin NSAID use and EOC risk, although not significant ([@bib25]). Similar differences in the magnitude of effect by race have been reported for breast cancer, where use of analgesic medications was associated with a stronger inverse relationship for risk of breast cancer among AA women compared with all other races ([@bib8]). As AA women have higher levels of inflammation, in general, compared with white women ([@bib2]; [@bib10]; [@bib18]), the potential benefit of taking anti-inflammatory drugs may be greater among AA women. The observed racial differences may also be because of a variety of factors that could vary by race, including genetic variants (e.g., prevalence of polymorphisms affecting cyclooxygenase activity), cultural attitudes toward analgesic use, or patterns of analgesic use. Further research needs to be conducted among racially diverse populations to confirm the observed racial differences in effect.

Although our findings suggest a protective effect for aspirin taken daily, at low doses, and for heart disease prevention, these three characteristics of use are highly correlated. A daily, low dose of aspirin is typically recommended for women at high risk of a cardiovascular event. In the WaTCH study, of the women who took aspirin for heart disease prevention, \>85% also reported low-dose aspirin use and a daily frequency of use. As the overwhelming majority of women taking aspirin for heart disease are the same women using aspirin daily and at low doses, it is difficult to determine whether indication, frequency, dose, or a combination of these characteristics of use is contributing to the reduction in risk. In addition, the observed association between aspirin use for heart disease prevention and EOC risk in the present study may be explained by the effects of other cardiovascular drugs (e.g., *β*-blockers, statins, angiotensin-converting enzyme inhibitors) taken concurrently with analgesic medications. To explore this possibility, the cardiovascular medication use of women taking aspirin for heart disease prevention (*n*=122) was examined; although a slightly higher prevalence of these cardiovascular medications was taken by the controls, a statistically significant difference in drug use was not observed (data not shown).

Although ovarian cancer is associated with a long latency period, our findings suggest that shorter durations of aspirin use (\<5 years) confer a stronger protective effect. Previous literature evaluating this relationship is inconsistent; some studies ([@bib1]; [@bib27]), including the large pooled analysis ([@bib26]), observed a stronger inverse association for shorter durations of aspirin use, whereas other studies reported a stronger protection for longer durations of use ([@bib20]; [@bib11]; [@bib23]). Although unclear, we speculate that the findings for shorter durations of use could be because of a few factors. A recall bias may be present, resulting in misclassification of duration. Women may have had difficulty accurately recalling their duration of use if it occurred for a longer period of time. In addition, as analgesic medications are routinely used for a variety of indications, women may not keep track of each use, leading to an underestimation of duration. The majority of women reporting a short duration of aspirin use began taking these medications within 2--5 years of their diagnosis (cases) or the time of interview (controls). It is possible that using aspirin during this time period may be more beneficial in protecting against ovarian cancer progression. In fact, cyclooxygenase inhibitors (i.e., aspirin) have been shown to decrease cell growth, increase apoptosis, and block angiogenesis ([@bib5]). Experimental studies are needed to explore a mechanistic explanation as to why a shorter duration of aspirin use may provide a greater protection against ovarian cancer.

The present study has several strengths. First, data from the largest study of EOC among AA women were utilised, resulting in a relatively large sample size to examine race-specific associations for analgesic use. Another strength is the detailed exposure assessment of analgesic use, allowing for effect estimates by frequency, duration, and indication of use. Despite these strengths, there were several limitations present in this study. Data on analgesic drug use were ascertained through self-report and may be subject to potential biases. In particular, if participants used several different types of these medications during their lifetime, it may be difficult to accurately report their use of each, especially with regard to the duration, frequency, and indication of use. However, the associations observed in the present study are consistent with those from the large pooled analysis of the Ovarian Cancer Association Consortium ([@bib26]) and other cohort studies ([@bib25]), although not significant. In addition, women with cardiovascular disease may be more acutely aware of their aspirin use; however, the prevalence of heart disease is similar among cases and controls (∼11%) and any resulting misclassification would bias the effect estimates towards the null. The lack of information on dose for non-aspirin NSAIDs and acetaminophen use was another limitation in this study. Because of the case--control study design, a potential selection bias may be present (i.e., women using analgesic medications may be more healthy and more likely to participate in the study). To evaluate the potential for a selection bias, the prevalence of analgesic use among AACES controls was compared with the available estimates for the general US population ([@bib29]). Although a direct comparison group for the demographic of the AACES study was unavailable, the prevalence of aspirin use among Black adults, aged ⩾18 years, was similar to AACES controls, and although possible, a selection bias is unlikely. Finally, although AACES is the largest study of EOC in AA, the sample of AA women within certain categories of exposure (e.g., indication of aspirin use, combined frequency, and duration of use) was small, limiting the power and precision of the effect estimates.

In conclusion, this study supports previous evidence that any NSAID use, but not acetaminophen, is inversely associated with EOC risk. The findings of the present study raise the intriguing possibility that the inverse association may be stronger in AA women compared with white women. This possibility emphasises the value of studying this question among racially diverse populations. Future research, specifically in large cohort studies, is needed in order to fully elucidate the impact of analgesic drug use on EOC risk in AA women, as well as other underrepresented racial groups.
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###### Characteristics[a](#t1-fn2){ref-type="fn"} of cases and controls, AACES (*N*=1272)

                                                       **Cases (*n***=**541)**   **Controls (*n***=**731)**   
  --------------------------------------------------- ------------------------- ---------------------------- ---------
  Age, years[b](#t1-fn3){ref-type="fn"}                                                                      
  \<50                                                       124 (23.1)                  198 (27.1)          0.02
  50--59                                                     188 (35.1)                  272 (37.2)           
  60--69                                                     143 (26.7)                  189 (25.8)           
  70+                                                         81 (15.1)                   72 (9.9)            
  Education                                                                                                  
  ⩽High school                                               242 (44.7)                  271 (37.1)          0.02
  Some post high school training                             139 (25.7)                  207 (28.3)           
  College or graduate degree                                 160 (29.6)                  253 (34.6)           
  Incom**e**                                                                                                 
  \<\$25 000                                                 254 (47.9)                  320 (44.3)          0.18
  \$25 000--\$49 999                                         130 (24.5)                  162 (22.4)           
  \$50 000--\$74 999                                          76 (14.4)                  121 (16.7)           
  \$75 000+                                                   70 (13.2)                  120 (16.6)           
  Parity (number of live births)                                                                             
  Nulliparous                                                105 (19.4)                  93 (12.7)           0.01
  1                                                          101 (18.7)                  137 (18.7)           
  2                                                          123 (22.7)                  194 (26.6)           
  3+                                                         212 (39.2)                  307 (42.0)           
  Family history of breast or ovarian cancer                                                                 
  No                                                         383 (72.5)                  577 (81.6)          0.0002
  Yes                                                        145 (27.5)                  130 (18.4)           
  Tubal ligation                                                                                             
  No                                                         351 (64.9)                  431 (59.0)          0.03
  Yes                                                        190 (35.1)                  300 (41.0)           
  BMI (kg m^−2^)                                                                                             
  \<25 (underweight and normal weight)                        79 (14.7)                  136 (18.6)          0.16
  25--29.9 (overweight)                                      139 (25.8)                  189 (25.9)           
  30+ (obese)                                                320 (59.5)                  405 (55.5)           
  Oral contraceptive use                                                                                     
  Never                                                      163 (30.1)                  151 (20.7)          0.0001
  Ever                                                       378 (69.9)                  580 (79.3)           
  Menopausal status                                                                                          
  Pre-menopausal                                              84 (15.6)                  134 (18.4)          0.29
  Peri-menopausal                                             73 (13.5)                  84 (11.5)            
  Post-menopausal                                            382 (70.9)                  511 (70.1)           
  Endometriosis                                                                                              
  No                                                         476 (88.6)                  696 (95.2)          0.00001
  Yes                                                         61 (11.4)                   35 (4.8)            
  Pelvic inflammatory disease                                                                                
  No                                                         491 (91.4)                  692 (94.9)          0.01
  Yes                                                         46 (8.6)                    37 (5.1)            
  Mild intensity physical activity                                                                           
  No                                                         389 (72.3)                  462 (63.2)          0.0007
  Yes                                                        149 (27.7)                  269 (36.8)           
  Moderate or strenuous intensity physical activity                                                          
  No                                                         301 (55.7)                  426 (58.3)          0.37
  Yes                                                        239 (44.3)                  305 (41.7)           
  Histologic subtype                                                                                         
  Serous                                                     367 (72.8)                                       
  Mucinous                                                    24 (4.7)                                        
  Endometrioid                                                70 (13.9)                                       
  Clear cell                                                  12 (2.4)                                        
  Mixed                                                       14 (2.8)                                        
  Other                                                       17 (3.4)                                        

Abbreviations: AACES=African American Cancer Epidemiology Study; BMI=body mass index.

Missing data on age for 5 women, income for 19 women, family history of a first-degree relative with breast or ovarian cancer for 37 women, BMI for 4 women, menopausal status for 4 women, endometriosis for 4 women, pelvic inflammatory disease for 6 women, mild intensity physical activity for 3 women, and moderate or strenuous intensity physical activity for 1 woman, and 37 cases for histologic subtype.

Age at diagnosis for cases and age at the time of interview for controls.

###### Estimated ORs and 95% CIs for the association of analgesic medication use and ovarian cancer risk

  ------------------------------------------- ---------------------------- ------------------------------- ---------------------------------------------------------------------------------------
  **Analgesic medication use**                                                                             
                                               **No. of cases (*n*=541)**   **No. of controls (*n*=731)**                  **Adjusted OR**[a](#t2-fn2){ref-type="fn"} **(95% CI)**
  Never users                                             362                            467                                                   1.00 (Referent)
  Any NSAID[b](#t2-fn3){ref-type="fn"} only               125                            197                                                  0.73 (0.54--0.98)
  Acetaminophen only                                       23                            33                                                   0.98 (0.53--1.81)
  Both NSAIDs and acetaminophen                            31                            34                                                   1.03 (0.58--1.84)
  **Aspirin use**                                                                                          
                                               **No. of cases (*n*=432)**   **No. of controls (*n*=560)**   **Adjusted OR**[a](#t2-fn2){ref-type="fn"}^,^[c](#t2-fn4){ref-type="fn"} **(95% CI)**
  Never users                                             362                            467                                                   1.00 (Referent)
  Ever use                                                 70                            93                                                   0.56 (0.35--0.92)
  **Non-aspirin NSAID use**                                                                                
                                               **No. of cases (*n*=474)**   **No. of controls (*n*=628)**   **Adjusted OR**[a](#t2-fn2){ref-type="fn"}^,^[c](#t2-fn4){ref-type="fn"} **(95% CI)**
  Never users                                             362                            467                                                   1.00 (Referent)
  Ever use                                                112                            161                                                  0.74 (0.52--1.05)
  **Acetaminophen use**                                                                                    
                                               **No. of cases (*n*=416)**   **No. of controls (*n*=534)**   **Adjusted OR**[a](#t2-fn2){ref-type="fn"}^,^[c](#t2-fn4){ref-type="fn"} **(95% CI)**
  Never users                                             362                            467                                                   1.00 (Referent)
  Ever use                                                 54                            67                                                   0.89 (0.49--1.62)
  ------------------------------------------- ---------------------------- ------------------------------- ---------------------------------------------------------------------------------------

Abbreviations: CI=confidence interval; NSAID=nonsteroidal anti-inflammatory drug; OR=odds ratio.

Adjusted for age, study site, education, income, parity, family history of first-degree relative with breast or ovarian cancer, tubal ligation, body mass index (BMI), oral contraceptive use, menopausal status, endometriosis, pelvic inflammatory disease, and physical activity.

Any NSAID use includes aspirin and non-aspirin NSAIDs, but not acetaminophen.

Also simultaneously adjusted for use of other analgesics.

###### Estimated ORs and 95% CIs for the association of frequency and duration of aspirin, non-aspirin NSAIDs, and acetaminophen use with ovarian cancer risk

                                    **Aspirin**   **Non-aspirin NSAID**   **Acetaminophen**                                              
  -------------------------------- ------------- ----------------------- ------------------- ----- ----- ------------------- ----- ----- -------------------
  Never users                           362                467             1.00 (Referent)    362   467    1.00 (Referent)    362   467    1.00 (Referent)
  **Frequency of use**                                                                                                                   
  \<30 Days/month                       15                 27             0.51 (0.21--1.25)   58    108   0.54 (0.35--0.83)   35    48    0.94 (0.49--1.81)
  Daily                                 55                 66             0.56 (0.34--0.94)   54    53    1.15 (0.70--1.91)   19    19    0.79 (0.33--1.92)
  **Duration of use**                                                                                                                    
  \<5 Years                             27                 41             0.52 (0.28--0.98)   33    51    0.81 (0.48--1.37)   15    25    0.97 (0.42--2.22)
  ⩾5 Years                              43                 52             0.60 (0.32--1.11)   79    110   0.71 (0.47--1.07)   39    42    0.87 (0.44--1.74)
  **Frequency, duration of use**                                                                                                         
  \<30 Days/month for \<5 years          7                 13             0.43 (0.14--1.34)   20    33    0.67 (0.35--1.27)    8    18    0.94 (0.34--2.63)
  Daily for \<5 years                   20                 28             0.56 (0.27--1.11)   13    18    1.13 (0.48--2.66)    7     7    1.12 (0.32--3.96)
  \<30 Days/month for ⩾5 years           8                 14             0.61 (0.17--2.22)   38    75    0.47 (0.28--0.79)   27    30    1.00 (0.45--2.21)
  Daily for ⩾5 years                    35                 38             0.56 (0.29--1.08)   41    35    1.17 (0.65--2.09)   12    12    0.58 (0.19--1.79)

Abbreviations: CI=confidence interval; NSAID= nonsteroidal anti-inflammatory drug; OR=odds ratio.

Adjusted for age, study site, education, income, parity, family history of first-degree relative with breast or ovarian cancer, tubal ligation, body mass index (BMI), oral contraceptive use, menopausal status, endometriosis, pelvic inflammatory disease, physical activity, and simultaneous adjustment of use of other analgesics (frequency, duration).
